Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology firm, will participate in two virtual investor conferences in January 2022.

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/05/2022 - 08:00 AM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following January investor conferences:

40th Annual J.P. Morgan Healthcare Conference, to be held virtually, on Thursday, January 13^th, 2022, at 9:45 a.m. ET, immediately followed by a Q&A session
B. Riley Virtual Oncology Conference, on Friday, January 28^th, 2022, at 11:00 a.m. ET

A live webcast of the presentations can be accessed through the Investors & Media section of Magenta’s website at https://investor.magentatx.com/events-and-presentations. A replay of each webcast will be available on Magenta’s website for 30 days following the events.

About Magenta Therapeutics
Magenta Therapeutics is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Massachusetts. For more information, please visit www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005293/en/

Leah Monteiro
Magenta Therapeutics
Vice President, Investor Relations
lmonteiro@magentatx.com

Source: Magenta Therapeutics

Keep reading

More on MGTA

May 3, 2023 Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
Mar 31, 2023 Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
Feb 2, 2023 Magenta Therapeutics to Explore Strategic Alternatives

All MGTA news

Trending in the feed

SNDK

Sandisk Reports Fiscal First Quarter 2027 Financial Results Open the live feed